Page last updated: 2024-11-03
riluzole and Bradyarrhythmia
riluzole has been researched along with Bradyarrhythmia in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 6.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 2.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Meyer, T | 1 |
| Maier, A | 1 |
| Borisow, N | 1 |
| Dullinger, JS | 1 |
| Splettstösser, G | 1 |
| Ohlraun, S | 1 |
| Münch, C | 1 |
| Linke, P | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)[NCT00231140] | Phase 2 | 40 participants | Interventional | 2005-12-31 | Terminated |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for riluzole and Bradyarrhythmia